AUPH Stock Up 32% after 6-Day Win Streak
Aurinia Pharmaceuticals (AUPH) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 32% return. The company has gained about $503 Mil in value over the last 6 days, with its current market capitalization at about $1.6 Bil. The stock remains 30.3% above its value at the end of 2024. This compares with year-to-date returns of 7.1% for the S&P 500.
AUPH develops and commercializes therapies addressing unmet medical needs, offering LUPKYNIS for treating adult patients with active lupus nephritis in the US and internationally. After this rally, is AUPH still a buy – or is it time to lock in gains? Deep dive with Buy or Sell AUPH.
Comparing AUPH Stock Returns With The S&P 500
The following table summarizes the return for AUPH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | AUPH | S&P 500 |
|---|---|---|
| 1D | 2.2% | -0.5% |
| 6D (Current Streak) | 31.6% | -1.4% |
| 1M (21D) | 56.6% | 1.1% |
| 3M (63D) | 41.6% | 11.5% |
| YTD 2025 | 30.3% | 7.1% |
| 2024 | -0.1% | 23.3% |
| 2023 | 108.1% | 24.2% |
| 2022 | -81.1% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has AUPH behaved after prior drops? See AUPH Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 49 S&P constituents with 3 days or more of consecutive gains and 20 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 39 | 6 |
| 4D | 10 | 4 |
| 5D | 0 | 7 |
| 6D | 0 | 2 |
| 7D or more | 0 | 1 |
| Total >=3 D | 49 | 20 |
Key Financials for Aurinia Pharmaceuticals (AUPH)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $175.5 Mil | $235.1 Mil |
| Operating Income | $-91.7 Mil | $18.4 Mil |
| Net Income | $-78.0 Mil | $5.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $59.9 Mil | $62.5 Mil |
| Operating Income | $13.7 Mil | $23.4 Mil |
| Net Income | $1.4 Mil | $23.3 Mil |
While AUPH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.